Seltorexant for Major Depressive Disorder

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

Recruiting Phase 3 Interventional Study
Depressive Disorder, Major
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 74
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
600 (estimated)
Sponsor
Janssen Research & Development, LLC · Industry
Who this trial is looking for

This trial is looking for adults and elderly individuals with major depressive disorder. Participants will take either the study drug or a placebo to see how well it helps their depression.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with major depressive disorder.
  • I have had at least one previous episode of depression.
  • My current episode of depression has lasted at least 2 weeks.
  • I weigh between 18 and 40 kg/m².
  • I am medically stable based on recent health checks.

You may not be able to join if

  • I have used ketamine or esketamine for my current episode of depression.
  • I have treatment-resistant depression.
  • I currently have any serious disorders like PTSD or OCD.
  • I have a history of any psychotic or bipolar disorder.
  • I have had serious suicidal thoughts or actions in the last 3 months.
  • I have a significant substance use disorder in the last 6 months.
  • I have a serious sleep disorder.
  • I am allergic to seltorexant or its ingredients.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive symptoms in participants with major depressive disorder (\[MDD\], a common mood disorder that causes a lasting feeling of sadness and a loss of interest in everyday activities) in double-blind treatment phase. Further, to evaluate long-term safety and to…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria: * Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features based upon clinical assessment and confirmed by the SCID-CT diagnosed with first depressive episode prior to age 5…
Contacts

Study Contact

844-434-4210

Participate-In-This-Study1@its.jnj.com

CONTACT